Public health authorities are currently scrambling to secure medical countermeasures for an outbreak of the Bundibugyo strain of the Ebola virus in the Democratic Republic of Congo. With 2,473 confirmed cases and 999 deaths reported by the government, the lack of approved vaccines or treatments for this specific strain—which carries a fatality rate of up … Read more
Roche has launched its Axelios gene sequencer, a new platform designed to perform large-scale DNA and RNA analysis, marking the company’s attempt to compete with industry leader Illumina. Roche aims to sell about 100 machines within the first year, targeting academic and research institutions to build a foundation for long-term growth in the $7.3 billion … Read more
Merck KGaA has announced an $11.3 billion agreement to acquire U.S.-based Bio-Techne, marking the German pharmaceutical giant’s largest acquisition since 2014. The deal, which offers $73 per share—a 24% premium over the closing price on Wednesday—is designed to bolster Merck’s life sciences division by integrating Bio-Techne’s extensive portfolio of research reagents, proteins, and analytical instruments … Read more
The U.S. government has begun shipping stockpiled doses of an experimental antibody drug, MBP134, from Mapp Biopharmaceutical to the Democratic Republic of Congo to combat a widening Bundibugyo Ebola outbreak. According to the U.S. Department of Health and Human Services, this shift in policy marks the first time Washington has released the treatment for clinical … Read more
From Terminal to Chronic: The New Era of Precision Oncology For decades, a cancer diagnosis often felt like a binary outcome. Today, that narrative is shifting. Thanks to a deeper understanding of the human genome, we are entering an era where cancer is increasingly managed as a chronic, long-term condition rather than an immediate death … Read more
A New Dawn for Pancreatic Cancer: Why the “RAS” Breakthrough Changes Everything For decades, a diagnosis of advanced pancreatic cancer felt like a closing door. With the highest mortality rate among major cancers, the standard of care—chemotherapy—often offered only a grueling path with limited time. However, a major shift is underway. Recent clinical trial data … Read more